Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PTX. Wow according to ST someone took a block of 2.5m at. 60.
Wow according to ST someone took a block of 2.5m at. 60.
PTX crossed above 50 day Exponential Moving Average @ .6198 Trigger as of 09/30/2016 12:08PM EDT
PTX is spiking all the sudden.
PTX crossed above 20 day Exponential Moving Average @ .6 Trigger as of 09/30/2016 09:38AM EDT. Buy out candidate. Keep on close watch. Watch for debt restructuring, I think that is the main catalyst traders are watching for. I am long.
NEW YORK, Sept. 29, 2016 /PRNewswire/ -- Delcath Systems, Inc. (DCTH) (the "Company"), an interventional oncology company focused on treatments for primary and metastatic liver cancers, today announced that it intends to offer shares of its common stock and warrants to purchase shares of common stock in an underwritten public offering. The completion of the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Roth Capital Partners is acting as the sole manager for the offering.
The Company intends to use the net proceeds from the offering (including any resulting from the exercise of the warrants, if any) for general corporate purposes, including, but not limited to, funding of its clinical trials, commercialization of its products, obtaining regulatory approvals, research, capital expenditures and working capital.
The securities described above are being offered by the Company pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC"). An electronic preliminary prospectus relating to the offering will be filed with the SEC and when filed will be available on the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147 or by accessing the SEC's website, www.sec.gov.
Think this is worth buying at 3 in AH?
I wish I was in Little Peter Hills moose hunting right now!
Always late it ain't like they have been to busy!
KTOVW. Just FYI in case someone wants to know. The warrants trade after hours. I did not know that. 750 so far AH today.
Barry Honig sold out,what a surprise.
Good PR on PTX yesterday.
What is the expiration on those warrants? OPXAW
Do you think KTOV would sell for 200m? I don't.
AVXL up big on deal.
If PTX gets bought out soon most of it is going to KTOVW.
100 would be about 1.5b mc.
You think the warrants can go to 100 dollars?
300m BO = 20 a share 15m fully diluted. 500m BO = 33 a share. KTOV. The further along they get the more it is worth. What is the price of the warrants at a stock price of 20?
30% of 2.7b is 810m. IMO 300m BO is very conservative. I would says 500m plus. KTOV
I think 3 times sales is the norm.
Ash here is some 2015 data. KTOV.
https://www.statista.com/statistics/253788/pfizers-top-products-based-on-revenues/
Norvasc actually sold more than Celebrex. Wow huge opportunity for KTOV.
Kei you off work already? Ha
That's 2014 data. Anyone have more recent numbers? KTOV
What are the celebrex sales figures? KTOV
Watch SYN. Unusual volume. I have been long in this one a long time.
KTOVW 1.20! I'll hold down the fort since I am off work on short term disability. Kei
Wow KTOVW 1.00
TEL AVIV, Israel, September 27, 2016 /PRNewswire/ --
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late stage drug development, announced today that its lead drug candidate KIT-302 has successfully completed an additional pharmacokinetic (PK) bioequivalence (BE) study and once more successfully met the U.S. Food and Drug Administration's (FDA) standards for establishing bioequivalence to the reference drugs. The current study evaluated a lower dosage (2.5 mg) of amlodipine than in Kitov's previous PK bioequivalence study for the KIT-302 product containing 10 mg of amlodipine, the results of which were announced by Kitov on May 10, 2016.
"We are pleased with the results of our additional pharmacokinetic BE study, which brings us closer towards submitting our New Drug Application to the FDA for KIT-302 as planned," stated Dr. J. Paul Waymack, Chairman of Kitov's Board and Chief Medical Officer.
The study compared the PK of Kitov's combination drug KIT-302 in a fixed dose combination consisting of 200 mg of celecoxib, indicated for osteoarthritis pain, and 2.5 mg of amlodipine, indicated for high blood pressure, to off-the-shelf branded 200 mg celecoxib capsules and 2.5 mg amlodipine tablets. These evaluations were conducted under both fed and fasted conditions. The results demonstrated that for both the Cmax (the maximum blood level achieved) and Area Under the Curve (the area under the concentration time curve for drug levels), the 90% confidence intervals for both the amlodipine and celecoxib components of KIT-302 were documented to be between 80% and 125% of the values obtained with the off-the-shelf drugs. With these study results, Kitov has again met the FDA standard for demonstrating BE under both fed and fasted conditions.
About KIT-302
KIT-302 is intended to treat pain caused by osteoarthritis (OA), as well as simultaneously treat hypertension, which is a common side effect of certain stand-alone drugs that treat osteoarthritis pain, as well as a common concomitant preexisting condition. KIT-302 is comprised of two U.S. Food and Drug Administration (FDA) approved drugs, celecoxib (the active ingredient in Pfizer's Celebrex®), for the treatment of pain caused by osteoarthritis and amlodipine besylate (the active ingredient in Pfizer's Norvasc®), a drug designed to treat hypertension. Kitov expects to submit a New Drug Application for KIT-302, which successfully completed a pivotal Phase III trial, with the U.S. Food and Drug Administration within the coming months.
Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.). Norvasc® is a registered trademark of Pfizer Inc.
About Kitov Pharmaceuticals
I picked up a few more this am. KTOVW
KTOV Director resigns.
http://www.streetinsider.com/dr/news.php?id=12074269
Request to posters. Please put the ticker in all post. It says time to back click to see what stock you are talking about. TIA.
ILNS is another one.
KTOV September presentationso.
http://kitovpharma.investorroom.com/presentations
Unusual activity on GBIM.
Watch XON to get some of that Zika money.
Thanks
Recovering from knee surgery,meds are knocking me out. Holy Moly. Go PTX.